系统综述与荟萃分析:亚洲常规临床实践中无干扰素直接抗病毒方案治疗慢性丙型肝炎基因1型的有效性与耐受性
该研究系统检索并荟萃分析了亚洲8个国家和地区41项研究共8574例HCV基因1型患者,评估无干扰素直接抗病毒方案在常规临床实践中的有效性与耐受性。达拉他韦/阿舒瑞韦的合并SVR率为89.9%(95%CI 88.6-91.1,I²=55.1%),雷迪帕韦/索磷布韦±利巴韦林为98.1%(95%CI 97.0-99.0,I²=41.0%)。基线肝硬化、基线耐药相关替换及肝细胞癌等因素影响SVR率。
要点
- 达拉他韦/阿舒瑞韦治疗HCV基因1型的合并SVR率为89.9%(95%CI 88.6-91.1,I²=55.1%)。
- 雷迪帕韦/索磷布韦±利巴韦林的合并SVR率为98.1%(95%CI 97.0-99.0,I²=41.0%)。
- 基线耐药相关替换使达拉他韦/阿舒瑞韦的SVR率降至65.4%,而无替换者为94.3%(P<0.001)。
核心结论
- 在亚洲常规临床实践中,全口服直接抗病毒方案治疗HCV基因1型患者可获得高治愈率,包括老年患者和终末期肾病患者。
研究设计与样本
- 系统综述与荟萃分析,纳入截至2017年5月31日发表的41项研究,来自8个国家和地区,共8574例HCV基因1型成人患者,评估常规临床实践中无干扰素直接抗病毒方案的SVR12/24。
主要发现
- 达拉他韦/阿舒瑞韦治疗基因1型的合并SVR率为89.9%(95%CI 88.6-91.1,I²=55.1%)。
- 雷迪帕韦/索磷布韦±利巴韦林治疗基因1型的合并SVR率为98.1%(95%CI 97.0-99.0,I²=41.0%)。
- 基线耐药相关替换使达拉他韦/阿舒瑞韦的SVR率显著降低:有替换者65.4% vs 无替换者94.3%(P<0.001)。
- 基线耐药相关替换对雷迪帕韦/索磷布韦±利巴韦林的SVR率影响较小:有替换者94.5% vs 无替换者99.2%(P=0.003)。
- 合并肝细胞癌患者接受雷迪帕韦/索磷布韦±利巴韦林的SVR率低于无肝细胞癌者:94.1% vs 98.7%(P=0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Direct-acting antiviral (DAA) regimens have shown high efficacy and tolerability for patients with HCV genotype 1/1b (GT1/1b) in clinical trials. However, robust real-world evidence of interferon (IFN)-free DAA treatment for HCV GT1-infected patients in Asia is still lacking. AIM: To systematically review and meta-analyse the effectiveness and tolerability of IFN-free DAA therapy for HCV GT1 infection in Asia. METHODS: We included studies that enrolled adult patients with HCV GT1 infection in routine clinical practice in Asia, using IFN-free DAA regimens, and reported sustained virological response (SVR) after 12/24 weeks end-of-treatment by 31 May 2017. The pooled SVR rates were computed with a random-effects model. Subgroup analysis and meta-regression as previously registered in PROSPERO were performed to determine how pre-planned variables might have affected the pooled estimates. RESULTS: We included 41 studies from eight countries and regions, comprising of 8574 individuals. The pooled SVR rates for GT1 were 89.9% (95% CI 88.6-91.1, I2 = 55.1%) with daclatasvir/asunaprevir (DCV/ASV) and 98.1% (95% CI 97.0-99.0, I2 = 41.0%) with ledipasvir/sofosbuvir ± ribavirin (LDV/SOF ± RBV). Baseline cirrhosis but not prior treatment history and age, attenuated the effectiveness of both regimens. Baseline resistance associated substitutions (RASs) severely attenuated SVR of DCV/ASV (65.4% vs 94.3%, P < 0.001) and only minimally with LDV/SOF ± RBV (94.5% vs 99.2%, P = 0.003). Patients with renal dysfunction treated with DCV/ASV showed a higher SVR rate (93.9% vs 89.8%, P = 0.046). Patients with hepatocellular carcinoma (HCC) LDV/SOF ± RBV achieved a lower SVR than those without HCC (94.1% vs 98.7%, P = 0.001). CONCLUSION: All oral DAA treatment of HCV GT1 resulted in high cure rates in Asian patients in routine clinical practice setting including elderly patients and those with end-stage renal disease.
引用
- Ji F, Wei B, Yeo YH, et al. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia. Aliment Pharmacol Ther. 2018. PMID: 29327780. doi:10.1111/apt.14507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。